Last reviewed · How we verify
ANG-3070
ANG-3070 is a Tyrosine kinase inhibitor Small molecule drug developed by Angion Biomedica Corp. It is currently in Phase 2 development for Diabetic kidney disease, Peripheral artery disease.
ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair.
ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair. Used for Diabetic kidney disease, Peripheral artery disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ANG-3070 |
|---|---|
| Sponsor | Angion Biomedica Corp |
| Drug class | Tyrosine kinase inhibitor |
| Target | TEK (TIE2 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
ANG-3070 inhibits TEK (TIE2) receptor signaling, which is involved in vascular endothelial growth and stabilization. By modulating angiopoietin-TEK pathway activity, the drug aims to restore vascular function and promote tissue healing in ischemic conditions. This mechanism is particularly relevant for improving perfusion and reducing inflammation in tissues with compromised blood supply.
Approved indications
- Diabetic kidney disease
- Peripheral artery disease
Common side effects
- Hypertension
- Edema
- Gastrointestinal disorders
Key clinical trials
- Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis (PHASE1)
- Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease (PHASE2)
- ANG-3070 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANG-3070 CI brief — competitive landscape report
- ANG-3070 updates RSS · CI watch RSS
- Angion Biomedica Corp portfolio CI
Frequently asked questions about ANG-3070
What is ANG-3070?
How does ANG-3070 work?
What is ANG-3070 used for?
Who makes ANG-3070?
What drug class is ANG-3070 in?
What development phase is ANG-3070 in?
What are the side effects of ANG-3070?
What does ANG-3070 target?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Target: All drugs targeting TEK (TIE2 receptor)
- Manufacturer: Angion Biomedica Corp — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Diabetic kidney disease
- Indication: Drugs for Peripheral artery disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing